BR9909869A - Composições perorais de liberação controlada de levosimendan - Google Patents

Composições perorais de liberação controlada de levosimendan

Info

Publication number
BR9909869A
BR9909869A BR9909869-5A BR9909869A BR9909869A BR 9909869 A BR9909869 A BR 9909869A BR 9909869 A BR9909869 A BR 9909869A BR 9909869 A BR9909869 A BR 9909869A
Authority
BR
Brazil
Prior art keywords
levosimendan
controlled release
peroral
peroral compositions
compositions
Prior art date
Application number
BR9909869-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Ilkka Larma
Maarit Bockman
Saila Antila
Lasse Lehtonen
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8551575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9909869(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of BR9909869A publication Critical patent/BR9909869A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
BR9909869-5A 1998-04-23 1999-04-23 Composições perorais de liberação controlada de levosimendan BR9909869A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI980901A FI980901A7 (fi) 1998-04-23 1998-04-23 Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
PCT/FI1999/000329 WO1999055305A2 (en) 1998-04-23 1999-04-23 Controlled release peroral compositions of levosimendan

Publications (1)

Publication Number Publication Date
BR9909869A true BR9909869A (pt) 2000-12-19

Family

ID=8551575

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9909869-5A BR9909869A (pt) 1998-04-23 1999-04-23 Composições perorais de liberação controlada de levosimendan

Country Status (37)

Country Link
US (1) US7045147B1 (cg-RX-API-DMAC10.html)
EP (1) EP1071397B1 (cg-RX-API-DMAC10.html)
JP (2) JP4566402B2 (cg-RX-API-DMAC10.html)
KR (1) KR100960597B1 (cg-RX-API-DMAC10.html)
CN (1) CN1248691C (cg-RX-API-DMAC10.html)
AR (1) AR019096A1 (cg-RX-API-DMAC10.html)
AT (1) ATE258425T1 (cg-RX-API-DMAC10.html)
AU (1) AU756641B2 (cg-RX-API-DMAC10.html)
BG (1) BG64839B1 (cg-RX-API-DMAC10.html)
BR (1) BR9909869A (cg-RX-API-DMAC10.html)
CA (1) CA2329234C (cg-RX-API-DMAC10.html)
CO (1) CO5070607A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ295194B6 (cg-RX-API-DMAC10.html)
DE (1) DE69914472T2 (cg-RX-API-DMAC10.html)
DK (1) DK1071397T3 (cg-RX-API-DMAC10.html)
EA (1) EA002829B1 (cg-RX-API-DMAC10.html)
EE (1) EE04220B1 (cg-RX-API-DMAC10.html)
ES (1) ES2215379T3 (cg-RX-API-DMAC10.html)
FI (1) FI980901A7 (cg-RX-API-DMAC10.html)
GE (1) GEP20032906B (cg-RX-API-DMAC10.html)
HR (1) HRP20000704B1 (cg-RX-API-DMAC10.html)
HU (1) HUP0101458A3 (cg-RX-API-DMAC10.html)
ID (1) ID27987A (cg-RX-API-DMAC10.html)
IL (2) IL138951A0 (cg-RX-API-DMAC10.html)
MX (1) MXPA00010367A (cg-RX-API-DMAC10.html)
NO (1) NO329809B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ507453A (cg-RX-API-DMAC10.html)
PL (1) PL197447B1 (cg-RX-API-DMAC10.html)
PT (1) PT1071397E (cg-RX-API-DMAC10.html)
RS (1) RS49962B (cg-RX-API-DMAC10.html)
SI (1) SI1071397T1 (cg-RX-API-DMAC10.html)
SK (1) SK285427B6 (cg-RX-API-DMAC10.html)
TR (1) TR200003102T2 (cg-RX-API-DMAC10.html)
TW (1) TWI224507B (cg-RX-API-DMAC10.html)
UA (1) UA68376C2 (cg-RX-API-DMAC10.html)
WO (1) WO1999055305A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200005632B (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
WO2004082615A2 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
EP2306823A4 (en) 2008-06-30 2012-09-26 Tocagen Inc 5-FLUOROCYTOSINE FORMULATIONS AND USES THEREOF
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス,インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症(PH-HF-pEF)を治療するためのレボシメンダン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203684A (en) 1982-04-05 1986-06-11 Merck Sharp & Dohme Granular formulation for the stabilization of unstable drugs or food supplements
US4716042A (en) 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A7 (fi) 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578L (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia

Also Published As

Publication number Publication date
EP1071397B1 (en) 2004-01-28
GEP20032906B (en) 2003-02-25
HK1034032A1 (en) 2001-10-12
SK285427B6 (sk) 2007-01-04
CA2329234C (en) 2008-06-10
EE200000617A (et) 2002-06-17
UA68376C2 (en) 2004-08-16
HUP0101458A2 (hu) 2002-03-28
JP2002512946A (ja) 2002-05-08
CN1248691C (zh) 2006-04-05
DK1071397T3 (da) 2004-04-05
KR20010071172A (ko) 2001-07-28
US7045147B1 (en) 2006-05-16
IL138951A (en) 2006-10-31
DE69914472D1 (de) 2004-03-04
CN1301163A (zh) 2001-06-27
CA2329234A1 (en) 1999-11-04
BG104959A (en) 2001-07-31
HUP0101458A3 (en) 2002-05-28
HRP20000704B1 (hr) 2009-11-30
JP2010083900A (ja) 2010-04-15
ATE258425T1 (de) 2004-02-15
YU63900A (sh) 2003-07-07
AU756641B2 (en) 2003-01-16
RS49962B (sr) 2008-09-29
DE69914472T2 (de) 2004-11-11
PT1071397E (pt) 2004-06-30
NO329809B1 (no) 2010-12-20
AR019096A1 (es) 2001-12-26
SI1071397T1 (en) 2004-06-30
FI980901A7 (fi) 1999-10-24
IL138951A0 (en) 2001-11-25
TR200003102T2 (tr) 2001-02-21
PL197447B1 (pl) 2008-03-31
KR100960597B1 (ko) 2010-06-07
WO1999055305A3 (en) 1999-12-29
NZ507453A (en) 2003-02-28
ZA200005632B (en) 2002-01-14
EP1071397A2 (en) 2001-01-31
CO5070607A1 (es) 2001-08-28
PL344078A1 (en) 2001-09-24
EA002829B1 (ru) 2002-10-31
NO20005313D0 (no) 2000-10-20
MXPA00010367A (es) 2002-06-04
WO1999055305A2 (en) 1999-11-04
TWI224507B (en) 2004-12-01
AU3524699A (en) 1999-11-16
NO20005313L (no) 2000-11-21
SK15542000A3 (sk) 2001-08-06
ES2215379T3 (es) 2004-10-01
ID27987A (id) 2001-05-03
HRP20000704A2 (en) 2001-04-30
BG64839B1 (bg) 2006-06-30
CZ295194B6 (cs) 2005-06-15
EE04220B1 (et) 2004-02-16
CZ20003780A3 (en) 2001-05-16
JP4566402B2 (ja) 2010-10-20
FI980901A0 (fi) 1998-04-23
EA200001098A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
BR9806752A (pt) Ftalazinonas.
BR0011770A (pt) Composto, e, composição farmacêutica
NO20011721L (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5- reseptoren
NZ506771A (en) Modified factor viii
DE69820632D1 (de) 2-phenyl-substituierte 1-(n-phenylaminoalkyl)-piperazin-derivate
BR0113970A (pt) Compostos de pirimidina e seu uso
NO20005981L (no) Anvendelse av 2-hydroksy-4-trifluorbenzosyrederivater som inhibitorer av aktivering av den nukleære transkripsjonsfaktor NF- <kappa>B
BG104959A (en) Control release peroral compositions of levosimendan
FR2742048B1 (fr) Utilisation de l'alpha-cyano-beta, beta-diphenylacrylate de 2-ethylhexyle pour ameliorer la stabilite de compositions cosmetiques contenant le p-methyl-benzylidene camphre en association avec un derive de dibenzoylmethane
EE04355B1 (et) Levosimendani kasutamine kopsuhüpertensiooni ravimi tootmises
BR0012072A (pt) Processo para o tratamento ou prevenção de vasoespasmo de enxerto coronário
DE69623945D1 (de) Polyketonpolymer-zusammensetzung
DE60104693D1 (de) Behandlung von septischem schock
TW362097B (en) 3-Phenyl-1, 4-dialkyl-1,2,4-triazolium salts and their use as antidepressants
WO2002047603A3 (en) Use of levosimendan for treating erictile dysfunction
CA2387920A1 (en) A new use of levosimendan

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA QUE O MESMO APRESENTA REIVINDICACOES QUE NAO ATENDEM AO REQUISITO DE ATIVIDADE INVENTIVA ( ART. 8O E ART. 13 DA LEI 9279/96 ).

B12B Appeal against refusal [chapter 12.2 patent gazette]